Federal Register / Vol. 66, No. 31 / Wednesday, February 14, 2001 / Notices 10321

Drug Schedule

Alpha-Methylthiofentanyl (9832) .............................................................................................................................................................. I

3-Methylthiofentanyl (9833) ..................................................................................................................................................................... I

Thiofentanyl (9835) .................................................................................................................................................................................. I

Amphetamine (1100) ............................................................................................................................................................................... II

Methamphetamine (1105) ........................................................................................................................................................................ II

Phenmetrazine (1631) ............................................................................................................................................................................. II

Methylphenidate (1724) ........................................................................................................................................................................... II

Amobarbital (2125) .................................................................................................................................................................................. II

Pentobarbital (2270) ................................................................................................................................................................................ II

Secobarbital (2315) ................................................................................................................................................................................. II

Glutethimide (2550) ................................................................................................................................................................................. II

Nabilone (7379) ....................................................................................................................................................................................... II

1-Phenylcyclohexylamine (7460) ............................................................................................................................................................. II

Phencyclidine (7471) ............................................................................................................................................................................... II

1-Piperidinocyclohexanecarbonitrile (8603) ............................................................................................................................................. II

Alphaprodine (9010) ................................................................................................................................................................................ II

Cocaine (9041) ........................................................................................................................................................................................ II

Codeine (9050) ........................................................................................................................................................................................ II

Dihydrocodeine (9120) ............................................................................................................................................................................ II

Oxycodone (9143) ................................................................................................................................................................................... II

Hydromorphone (9150) ............................................................................................................................................................................ II

Diphenoxylate (9170) ............................................................................................................................................................................... II

Benzoylecgonine (9180) .......................................................................................................................................................................... II

Ethylmorphine (9190) .............................................................................................................................................................................. II

Hydrocodone (9193) ................................................................................................................................................................................ II

Levomethorphan (9210) .......................................................................................................................................................................... II

Levorphanol (9220) .................................................................................................................................................................................. II

Isomethadone (9226) ............................................................................................................................................................................... II

Meperidine (9230) .................................................................................................................................................................................... II

Methadone (9250) ................................................................................................................................................................................... II

Methadone-intermediate (9254) .............................................................................................................................................................. II

Morphine (9300) ...................................................................................................................................................................................... II

Thebaine (9333) ...................................................................................................................................................................................... II

Levo-alphacetylmethadol (9648) ............................................................................................................................................................. II

Oxymorphone (9652) ............................................................................................................................................................................... II

Noroxymorphone (9668) .......................................................................................................................................................................... II

Alfentanil (9737) ....................................................................................................................................................................................... II

Sufentanil (9740) ..................................................................................................................................................................................... II

Fentanyl (9801) ........................................................................................................................................................................................ II

The firm plans to manufacture small

quantities of the listed controlled

substances to make deuterated and nondeuterated drug reference standards

which will be distributed to analytical

and forensic laboratories for drug testing

programs.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than April 16,

2001.

Dated: January 25, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–3752 Filed 2–13–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated September 25, 2000,

and published in the Federal Register

on October 3, 2000, (65 FR 59018),

Chattem Chemicals, Inc., 3801 St. Elmo

Avenue, Building 18, Chattanooga,

Tennessee 37409, made application by

letter to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

N-Ethylamphetamine (1475) ......... I

Drug Schedule

4-Methoxyamphetamine (7411) .... I

2,5-Dimethoxyamphetamine

(7396) ........................................ I

Difenoxin (9168) ........................... I

Methylphenidate (1724) ................ II

Pentobarbital (2270) ..................... II

Secobarbital (2315) ...................... II

Diphenoxylate (9170) ................... II

Hydrocodone (9193) ..................... II

The firm plans to bulk manufacture

the listed controlled substances to

produce products for distribution to its

customers.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Chattem Chemicals, Inc.

to manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Chattem Chemicals, Inc. to

ensure that the company’s registration is

consistent with the public interest. This

investigation included inspection and

testing of the company’s physical

security systems, verification of the

10322 Federal Register / Vol. 66, No. 31 / Wednesday, February 14, 2001 / Notices

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: January 25, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–3750 Filed 2–13–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated October 31, 2000, and

published in the Federal Register on

November 14, 2000, (65 FR 68158),

Stepan Company, Natural Products

Department, 100 W. Hunter Avenue,

Maywood, New Jersey 07605, made

application by renewal to the Drug

Enforcement Administration (DEA) to

be registered as an importer of coca

leaves (9040), a basic class of controlled

substance listed in Schedule II.

The firm plans to import the coca

leaves to manufacture bulk controlled

substance.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Stepan Company, Natural

Products Department to import coca

leaves is consistent with the public

interest and with United States

obligations under international treaties,

conventions, or protocols in effect on

May 1, 1971, at this time. DEA has

investigated Stepan Company, Natural

Products Department on a regular basis

to ensure that the company’s continued

registration is consistent with the public

interest. This investigation included

inspection and testing of the company’s

physical security systems, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to section 1008(a) of

the Controlled Substances Import and

Export Act and in accordance with Title

21, Code of Federal Regulations, section

1301.34, the above firm is granted

registration as an importer of the basic

class of controlled substance listed

above.

Dated: January 25, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–3751 Filed 2–13–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Pension and Welfare Benefits

Administration

Extension of Information Collection;

Comment Request; Prohibited

Transaction Exemption 91–55

ACTION: Notice.

SUMMARY: The Department of Labor, as

part of its continuing effort to reduce

paperwork and respondent burden,

conducts a preclearance consultation

program to provide the general public

and Federal agencies with an

opportunity to comment on proposed

and continuing collections of

information in accordance with the

Paperwork Reduction Act of 1995 (PRA

95) 44 U.S.C. 3506(c)(2)(A). This helps

to ensure that requested data can be

provided in the desired format,

reporting burden (time and financial

resources) is minimized, collection

instruments are clearly understood, and

the impact of collection requirements on

respondents can be properly assessed.

Currently, the Pension and Welfare

Benefits Administration is soliciting

comments concerning the information

collection request (ICR) incorporated in

Prohibited Transaction Exemption 91–

55, Transactions Between Individual

Retirement Accounts and Authorized

Purchasers of American Eagle Coins. A

copy of the ICR may be obtained by

contacting the office listed in the

Addresses section of this notice.

DATES: Written comments must be

submitted to the office shown in the

Addresses section below on or before

April 16, 2001.

ADDRESSES: Gerald B. Lindrew, Office of

Policy and Research, U.S. Department of

Labor, Pension and Welfare Benefits

Administration, 200 Constitution

Avenue, NW, Washington, D.C. 20210.

Telephone: (202) 219–4782 (this is not

a toll-free number); FAX: (202) 219–

4745. These are not toll-free numbers.

SUPPLEMENTARY INFORMATION:

I. Background

Prohibited Transaction Exemption

91–55 permits purchases and sales by

certain ‘‘individual retirement

accounts,’’ as defined in Internal

Revenue Code section 408 (IRAs) of

American Eagle bullion coins (‘‘Coins’’)

in principal transactions from or to

broker-dealers in Coins that are

‘‘authorized purchasers’’ of Coins in

bulk quantities from the United States

Mint and which are also ‘‘disqualified

persons,’’ within the meaning of Code

section 4975(e)(2), with respect to IRAs.

The exemption also describes the

circumstances under which an interestfree extension of credit in connection

with such sales and purchases is

permitted. In the absence of an

exemption, such purchases and sales

and extensions of credit would be

impermissible under the Employee

Retirement Income Security Act of 1974

(ERISA).

The information collection request for

this exemption includes three

requirements. First, certain information

related to covered transactions in Coins

must be disclosed by the authorized

purchaser to persons who direct the

transaction for the IRA. Currently, it is

standard industry practice that most of

this information is provided to persons

directing investments in an IRA when

transactions in Coins occur. The

exemption also requires that the

disqualified person maintain for a

period of at least six years such records

as are necessary to allow accredited

persons, as defined in the exemption, to

determine whether the conditions of the

transaction have been met. Finally, an

authorized purchaser must provide a

confirmation statement with respect to

each covered transaction to the person

who directs the transaction for the IRA.

The recordkeeping requirement

facilitates the Department’s ability to

make findings under section 408 of

ERISA and section 4975(c) of the Code.

The confirmation and disclosure

requirements protect a participant or

beneficiary investing in IRAs transacting

in Coins with authorized purchasers by

providing the investor or the person

directing his or her investments with

timely information about the market in

Coins and about the individual’s

account in particular.

II. Desired Focus of Comments

The Department of Labor is

particularly interested in comments

that:

• Evaluate whether the proposed

collection of information is necessary

for the proper performance of the